What's in Swedish Orphan Biovitrum's pipeline?

Swedish Orphan Biovitrum has 17 drugs in our index: 3 marketed, 0 filed, 6 in Phase 3, 2 in Phase 2, 5 in Phase 1.

Which companies overlap with Swedish Orphan Biovitrum's portfolio?

Top competitors by shared drug class: Alexion Pharmaceuticals, Inc., Amgen, Arbeitsgemeinschaft medikamentoese Tumortherapie, Assistance Publique - Hôpitaux de Paris, Azienda Ospedaliera Universitaria Integrata Verona.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/swedish-orphan-biovitrum.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Swedish Orphan Biovitrum — Portfolio Competitive Intelligence Brief

Swedish Orphan Biovitrum pipeline: 3 marketed, 0 filed, 6 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 6 Phase 3 2 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Kepivance (Palifermin)	Kepivance (Palifermin)	marketed	Fibroblast growth factor (FGF) receptor agonist	FGFR2 (Fibroblast Growth Factor Receptor 2)	Oncology
Alprolix	Alprolix	marketed			Other
ELOCTA	ELOCTA	marketed
Palifermin before only	Palifermin before only	phase 3	Fibroblast growth factor (FGF) analog	FGFR2 (Fibroblast Growth Factor Receptor 2)	Oncology
Placebo matching Pegcetacoplan	Placebo matching Pegcetacoplan	phase 3	Complement C3 inhibitor (aptamer)	Complement C3	Immunology / Rare Disease
SEL-212 high-dose	SEL-212 high-dose	phase 3	Uricase with immunosuppressant combination	Uric acid (via pegsiticase uricase enzyme)	Rheumatology / Gout
Palifermin before and after	Palifermin before and after	phase 3	Keratinocyte growth factor (KGF) receptor agonist	FGFR2 (Fibroblast Growth Factor Receptor 2)	Oncology
Physician's Choice medications	Physician's Choice medications	phase 3	Physician's Choice		Multiple Therapeutic Areas
SEL-212 low-dose	SEL-212 low-dose	phase 3	Monoclonal antibody	CD19	Oncology

Therapeutic area mix

Oncology · 4
Immunology · 1
Immunology / Rare Disease · 1
Multiple Therapeutic Areas · 1
Other · 1
Rheumatology / Gout · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Alexion Pharmaceuticals, Inc. · 1 shared drug class
Amgen · 1 shared drug class
Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Azienda Ospedaliera Universitaria Integrata Verona · 1 shared drug class
Baxalta now part of Shire · 1 shared drug class
Bayer · 1 shared drug class
AgeneBio · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Swedish Orphan Biovitrum:

Cite this brief

Drug Landscape (2026). Swedish Orphan Biovitrum — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/swedish-orphan-biovitrum. Accessed 2026-05-16.